Myeloablative Treatment Supported by Autologous Stem Cell Infusion with Neuroblastoma

Kyung Ha Ryu, Ju Young Seoh, Pil Sang Jang, Chul Woo Kim, Sang Hyeok Koh, Hee Young Shin, Hyo Seop Ahn

Research output: Contribution to journalArticlepeer-review


Bcr-abl antisense oligodeoxynucleotides (AS-ODNs) have provided evidence of an antileukemia effect when tested in vitro against Philadelphia-positive cells. In order to investigate the efficacy of AS-ODNs as purging agents in chronic myeloid leukemia (CML) patients, K562 cells, a human CML cell line, were treated in vitro with various types of AS-ODNs and interferon-α. Cells were treated in vitro for 0 and 36 hr with 40 μg/mL of AS-ODNs, respectively, and incubated at 37°C for 36 hr. Cytotoxic effects were measured by counting the number of viable cells as well as by MTT test. Clonogenic activities were evaluated by methylcellulose culture for 2 weeks. The effects of purging agents on the rearrangement of bcr-abl gene were evaluated by RT-PCR. AS-ODNs inhibited the proliferation of K562 cells with time in cell count assay and MTT test. AS-ODNs were superior to INF-α in inhibiting clonogenic activity (recovery rate; 26.3% vs 64.0%). After incubation with bcr-abl AS-ODNs primers and mRNA isolated from K562 cells, positive bands were abolished, especially of b3a2 type and phosphorothioate type. Our results suggest that AS-ODNs mediated purging may be one of the efficient methods and that autograft may be an alternative treatment for allograft in high-risk group patients of CML if they do not have a stem cell donor.

Original languageEnglish
Pages (from-to)184-190
Number of pages7
JournalJournal of Korean Medical Science
Issue number2
StatePublished - Apr 2003


  • Leukemia, myeloid, chronic
  • Oligonucleotides, antisense
  • Philadephia chromosome


Dive into the research topics of 'Myeloablative Treatment Supported by Autologous Stem Cell Infusion with Neuroblastoma'. Together they form a unique fingerprint.

Cite this